Vanda Pharmaceuticals (VNDA)

What Moves the Stock

1. 01Hetlioz prescription volume trends and market penetration in Non-24 and Smith-Magenis Syndrome patient populations
2. 02Clinical trial readouts for pipeline candidates or label expansion studies
3. 03FDA regulatory decisions on new drug applications or supplemental approvals
4. 04Reimbursement coverage decisions from major payers affecting product access
5. 05Partnership announcements or licensing deals that validate platform or provide non-dilutive funding
6. 06Cash runway concerns and potential financing events given negative cash flow profile
7. 07Hetlioz (tasimelteon) for rare circadian rhythm sleep disorders - primary revenue driver
8. 08Fanapt (iloperidone) for schizophrenia treatment - secondary product

VNDA Chart

My Notes

• growth/speculative - The stock attracts investors focused on turnaround potential and pipeline optionality rather than current…
• Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples…
• Watch on earnings: Quarterly Hetlioz prescription data from third-party sources (IQVIA, Symphony Health) showing volume trends, Operating cash flow trajectory and quarterly burn rate to assess runway extension or contraction, Gross-to-net percentage (discount from list price) indicating payer pressure and rebate trends.